Dexamethasone and Diphenhydramine Withdrawal and Quality of Life Assessment in Breast Cancer Patients Receiving Weekly Paclitaxel
Brazilian Journal of Oncology · 20.05.2026 · 22 (CP)
DOI: 10.1055/s-0045-1814367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brazilian Journal of Oncology, erschienen am 20.05.2026. Verfasst von Letícia de Jesus Rossato und 10 weiteren Autor:innen.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Maintenance of quality of life (QoL) is an important endpoint in cancer patients. Several studies have demonstrated that chemotherapy in breast cancer patients is related to worsening QoL scores. Taxanes are widely used in breast cancer treatment, and premedication omission in weekly paclitaxel has been evaluated in clinical trials and is a safe strategy. Nowadays there is lack of data if premedication withdrawal can improve QoL given the shortage of studies using a comparative group that keeps premedication. Materials and Methods We evaluated QoL scores in 60 breast cancer patients receiving weekly paclitaxel in 2 comparative groups: one that omitted and another that kept premedication, according to infusion-related reaction. The primary endpoint was the evaluation of QoL scores in both groups through the European Organization for Research and Treatment of Cancer's (EORTC) 30-item Core Quality of Life questionnaire (QLQ-C30) and 23-item Quality of Life Questionnaire–Breast Cancer Module (QLQ-BR23) at weeks 1, 2, 3, 4, 5, 9, and 12 of treatment. The secondary endpoint was the frequency of highest-grade adverse events through the adapted Dexamethasone Symptom Questionnaire in both groups.
Results
According to the QLQ-C30 and the QLQ-BR23, in the 2 groups, QoL showed no statistically significant differences related to premedication omission, neither did the frequency of highest-grade adverse events.
Conclusion
Although the absence of statistical differences in the QoL scores regarding premedication omission, some specific domains seem to deteriorate in patients receiving premedication. Future randomized trials exploring tailored questionnaires with specific domains and visual scales may be more accurate to detect QoL differences related to premedication.
Zitieren
APA
Rossato, L. D. J., Gonçalves, L. L., Bischoff, E., Zaffaroni, F., Borges, G. T., Mancio, I., Mittmann, L. B., Thomé, B. L., Souza, G. D. A. B. D., Maia, I. S., & Prolla, G. (2026). Dexamethasone and Diphenhydramine Withdrawal and Quality of Life Assessment in Breast Cancer Patients Receiving Weekly Paclitaxel. Brazilian Journal of Oncology, 22(CP). https://doi.org/10.1055/s-0045-1814367
Vancouver
Rossato LDJ, Gonçalves LL, Bischoff E, Zaffaroni F, Borges GT, Mancio I, et al. Dexamethasone and Diphenhydramine Withdrawal and Quality of Life Assessment in Breast Cancer Patients Receiving Weekly Paclitaxel. Brazilian Journal of Oncology. 2026;22(CP). doi:10.1055/s-0045-1814367
BibTeX
@article{Rossato2026,
author = {Rossato, Letícia de Jesus and Gonçalves, Larissa Lacerda and Bischoff, Eduardo and Zaffaroni, Facundo and Borges, Gabriela Turra and Mancio, Isabella and Mittmann, Laura Brasil and Thomé, Bibiana Liberman and Souza, Gabriela de Azevedo Bastian de and Maia, Isabela Semmelmann and Prolla, Gabriel},
title = {Dexamethasone and Diphenhydramine Withdrawal and Quality of Life Assessment in Breast Cancer Patients Receiving Weekly Paclitaxel},
journal = {Brazilian Journal of Oncology},
year = {2026},
volume = {22},
number = {CP},
doi = {10.1055/s-0045-1814367}
}
EUVIMED